



Interaction of Purinergic P2X4 and P2X7 Receptor Subunits

Markus Schneider^{1†}, Kirsten Prudic^{1†}, Anja Pippel¹, Manuela Klapperstück¹, Ursula Braam², Christa E. Müller³, Günther Schmalzing² and Fritz Markwardt^{1*}

¹ Julius-Bernstein-Institute for Physiology, Martin-Luther-University, Halle, Germany, ² Molecular Pharmacology, RWTH Aachen University, Aachen, Germany, ³ Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany

OPEN ACCESS

Edited by:

Kenneth A. Jacobson,
National Institutes of Health (NIH),
United States

Reviewed by:

Ichiro Maruyama,
Okinawa Institute of Science
and Technology, Japan
Dietmar Krautwurst,
Leibniz Association (LG), Germany

*Correspondence:

Fritz Markwardt
fritz.markwardt@medizin.uni-halle.de

[†] These authors have contributed
equally to this work.

Specialty section:

This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology

Received: 11 September 2017

Accepted: 09 November 2017

Published: 22 November 2017

Citation:

Schneider M, Prudic K, Pippel A,
Klapperstück M, Braam U,
Müller CE, Schmalzing G and
Markwardt F (2017) Interaction
of Purinergic P2X4 and P2X7
Receptor Subunits.
Front. Pharmacol. 8:860.
doi: 10.3389/fphar.2017.00860

P2X4 and P2X7 are members of the P2X receptor family, comprising seven isoforms (P2X1–P2X7) that form homo- and heterotrimeric non-specific cation channels gated by extracellular ATP. P2X4 and P2X7 are widely coexpressed, particularly in secretory epithelial cells and immune and inflammatory cells, and regulate inflammation and nociception. Although functional heteromerization has been established for P2X2 and P2X3 subunits expressed in sensory neurons, there are contradictory reports regarding a functional interaction between P2X4 and P2X7 subunits. To resolve this issue, we coexpressed P2X4 and P2X7 receptor subunits labeled with green (EGFP) and red (TagRFP) fluorescent proteins in *Xenopus laevis* oocytes and investigated a putative physical interaction between the fusion proteins by Förster resonance energy transfer (FRET). Coexpression of P2X4 and P2X7 subunits with EGFP and TagRFP located in the extracellular receptor domains led to significant FRET signals. Significant FRET signals were also measured between C-terminally fluorophore-labeled full-length P2X4^{1–384} and C-terminally truncated fluorescent P2X7^{1–408} subunits. We furthermore used the two-electrode voltage clamp technique to investigate whether human P2X4 and P2X7 receptors (hP2X4, hP2X7) functionally interact at the level of ATP-induced whole-cell currents. Concentration–response curves and effects of ivermectin (P2X4-potentiating drug) or BzATP (P2X7-specific agonist) were consistent with a model in which coexpressed hP2X4 and hP2X7 do not interact. Similarly, the effect of adding specific inhibitors of P2X4 (PSB-15417) or P2X7 (oATP, A438079) could be explained by a model in which only homomers exist, and that these are blocked by the respective antagonist. In conclusion, we show that P2X4 and P2X7 subunits can form heterotrimeric P2X4/P2X7 receptors. However, unlike observations for P2X2 and P2X3, coexpression of P2X4 and P2X7 subunits does not result in a novel electrophysiologically discriminable P2X receptor phenotype.

Keywords: P2X7, P2X4, voltage clamp, fluorescence, FRET, interaction, subunit

INTRODUCTION

P2X receptors are non-selective cation channels that are opened by extracellular ATP. The presence of ATP is considered a danger-associated signal (DAMP, danger-associated molecular pattern), because ATP is released from cells during damage, hypoxia, or cell membrane stretching (Di Virgilio, 2007; Praetorius and Leipziger, 2009). P2X receptors are homo- or heterotrimers that

assemble from a repertoire of seven possible subunits (P2X1–7) (Nicke et al., 1998; Aschrafi et al., 2004). All P2X subunits share similar membrane topology: intracellular N- and C-termini, two membrane-spanning domains (TM1 and TM2), and a large extracellular loop comprising the ATP binding site. The TM2 domains form the gate and the selectivity filter (Baconguis et al., 2013; Habermacher et al., 2015; Pippel et al., 2017). In addition to homotrimeric P2X receptors, P2X subunits can form heteromeric ion channels. The existence of P2X2/P2X3 heteromers in sensory neurons is well established (Lewis et al., 1995). A large number of other heteromers have been characterized in heterologous expression systems. However, their function in native tissue remains to be established (Saul et al., 2013).

The P2X4 and P2X7 subunit isoforms are widely coexpressed, particularly in secretory epithelial cells and cells of the immune and inflammatory system. The P2X7 subunit has the highest amino acid sequence similarity to the P2X4 subtype (Burnstock and Knight, 2004; Surprenant and North, 2008). Furthermore, the genes encoding both of these subunits colocalize on human chromosome 12, where they are separated by only 24 kbp (Craigie et al., 2013). P2X7 mRNA levels are reduced in P2X4 knockout mice, and vice versa (Craigie et al., 2013). In contrast, shRNA-mediated downregulation of P2X7 mRNA leads to increased P2X4 expression. Knockdown of P2X4 mRNA is reported to result in a compensatory increase in P2X7 protein expression (Weinhold et al., 2010).

Early co-immunoprecipitation studies of P2X subunit interactions excluded the interaction of P2X7 subunits with other subtypes (Torres et al., 1999), although later studies reported evidence of P2X4/P2X7 heteromerization (Guo et al., 2007). Subsequent investigations, however, have questioned the existence of P2X4/P2X7 heteromeric receptors (Nicke, 2008; Antonio et al., 2011; for reviews, see Craigie et al., 2013; Saul et al., 2013).

Here, we investigated physical and functional interactions P2X4 and P2X7 subunits heterologously expressed in *Xenopus* oocytes by measuring P2X4/P2X7-dependent Förster (or fluorescence) resonance energy transfer (FRET) signals and ion currents in *Xenopus* oocytes.


MATERIALS AND METHODS

Reagents


Unless otherwise stated, we purchased chemicals and molecular biology reagents from Sigma–Aldrich (Taufkirchen, Germany), Merck (Darmstadt, Germany), and New England Biolabs (Schwalbach, Germany). The novel hP2X4-selective antagonist PSB-15417 was provided by Prof. Christa Müller (Institute of Pharmaceutical Chemistry, University of Bonn, Germany) via Orion (Espoo, Finland).

Expression of hP2X4 and hP2X7 Subunits in *Xenopus laevis* Oocytes

The following oocyte expression plasmids encoding full-length human (h) and rat (r) subunits of ligand-gated ion channels were available from our previous work (reference sequence NCBI



IDs and references in parenthesis): hP2X4 (ID: NP_002551.2, Rettinger et al., 2000); rP2X4 (ID: NP_113782.1, Aschrafi et al., 2004); hP2X7 (ID: NP_002553.3, Klapperstück et al., 2000), hP2X7^{1–408} (C-terminally truncated by placing a premature TGA stop codon directly after the hP2X7⁴⁰⁸H codon, Becker et al., 2008); and hGLYRA1 (ID: NP_000162.2, Büttner et al., 2001). We amplified full-length cDNA encoding the rat P2X7 subunit (ID: NP_062129.1) by RT-PCR from total rat brain RNA isolated using the RNA Clean System (Angewandte Gentechnologie Systeme, Heidelberg, Germany) and gene-specific primers (Supplementary Table 1) based on the published rP2X7 sequence (Surprenant et al., 1996). The PCR product was first inserted into the pGEM5 ZF(+) vector (X65308; Promega, Mannheim, Germany) by TA cloning (Kovalic et al., 1991) and then directionally subcloned it into the pNKS2 oocyte expression




vector (Gloor et al., 1995) using *AatII* and *XbaI* restriction sites introduced via PCR (underlined in Supplementary Table 1). We previously reported using the rP2X7-pNKS2 construct without describing its origin (Hausmann et al., 2006).

We obtained a synthetic gene encoding the *Caenorhabditis elegans* glutamate-gated chloride channel α (GluCl) optimized for crystallization (GluCl_{cryst}) (Hibbs and Gouaux, 2011) from ShineGene (Shanghai, China). This was subcloned into a Gateway-compatible pNKS2 vector (Stolz et al., 2015) using the Gateway cloning system (Invitrogen, Karlsruhe, Germany). We previously verified by blue native PAGE that ectopic GluCl_{cryst} efficiently assembles into a homopentamer in *Xenopus laevis* oocytes (Dopychai et al., 2015). A plasmid harboring full-length cDNA for hTRPV2 (DNASU plasmid ID HsCD00045624) was obtained from the DNASU Plasmid Repository (The Biodesign Institute, Arizona State University, Tempe, AZ, United States) and subcloned using the Gateway system into the pNKS2 vector.

We generated fluorophore-labeled channel constructs with the enhanced green fluorescent protein or Tag red fluorescent protein (referred to as GFP or RFP throughout, respectively) located at the N-terminus (or ectodomain) or C-terminus (indicated by adding the name of the label (GFP or RFP) at the left (ectodomain) or right (C-terminus) of the fusion protein name). To N-terminally labeling hGLYRA1 (the human glycine receptor α 1 subunit) with GFP, we first located the signal peptidase cleavage site at between codon position ²⁸A and ²⁹A using the SignalP 4.1 server¹ (Petersen et al., 2011). Next, we introduced unique *NdeI* and *EcoR47III* restriction sites using the QuikChange site-directed mutagenesis protocol (Stratagene, Heidelberg, Germany, (Braman et al., 1996) with primers O-1699/O-1700 (Supplementary Table 2). Finally, we PCR-amplified the full-length cDNA for GFP from the EGFP-N1 vector (Invitrogen, Karlsruhe, Germany) using

¹<http://www.cbs.dtu.dk/services/SignalP>



primers O-1701/O-1702 (Supplementary Table 3), purified, and directionally cloned between *NdeI* and *EcoR47III* sites to construct the SP-GFP-hGLYRA1 vector (where SP indicates the position of the signal peptide). This construct encodes an additional alanine residue directly 5' of the GFP moiety and is predicted by the SignalP 4.1 server to undergo signal peptidase cleavage at the same residues as wild type (wt) hGLYRA1.


We used the megaprimer method (Perez et al., 2006) for fluorescence labeling of all the other ion channel constructs (primers are listed in Supplementary Table 2). Single (GFP or RFP) or tandem (GFP-RFP) labels were added to the C-termini of ion channel constructs by in-frame fusion with full-length GFP and RFP sequences with the RFP sequence amplified from the TagRFP-N vector (Evrogen, Moscow, Russia). Likewise, we inserted GFP and RFP cDNA either singly or in tandem after *P2X4* codon 122 or *P2X7* codon 125. Our rationale was that rP2X4 receptors containing a fluorescent pHluorin moiety after ¹²²K have previously been shown to function like wt-rP2X4 (Xu et al., 2014). A previous sequence alignment showed that rP2X4 ¹²²K (hP2X4 ¹²²A) corresponds to ¹²⁵R for both rP2X7 and hP2X7 (Kawate et al., 2009).

We synthesized capped cRNA using a modified method (Klapperstück et al., 2000) involving co-transcriptional incorporation of the anti-reverse cap analog ($m_2^{7,3'}\text{-}^{\text{O}}\text{GpppG}$; NU-855; Jena Bioscience, Germany) to ensure the correct

orientation at the ATG start codon of the cRNA (Grudzien-Nogalska et al., 2007; Stolz et al., 2015). We surgically isolated oocytes from tricaine-anesthetized *Xenopus laevis* (*Xenopus* Express, Vernassal, France) using sterile surgical techniques and defolliculated them with collagenase NB 4G (Serva, Heidelberg, Germany). We injected oocytes of Dumont stages V–VI individually with 5–50 ng *P2X4* and/or *P2X7* cRNA to obtain similar ATP-evoked current amplitudes mediated by the encoded *P2X4* and *P2X7* receptors. To optimize FRET efficiency (FE), we adjusted the amount of mRNA used to coexpress GFP- and RFP-labeled constructs to obtain higher fluorescence signals from channels labeled with GFP than with RFP (Ma et al., 2014). We incubated the oocytes at 19°C in sterilized frog Ringer solution (Mg/Ca-ORi: 100 mM NaCl, 2.5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂, and 10 mM HEPES, pH 7.4) supplemented with penicillin (100 U/ml) and streptomycin (100 µg/ml) or with gentamycin (50 µg/ml) (Flittiger et al., 2010). This study was carried out in accordance with the recommendations of the EC Directive 86/609/EEC for animal experimentation. The protocol was approved by the local animal welfare committee (reference no. 53a-42502/2–173; Magdeburg, Germany).

FRET Experiments

We measured fluorescence signals from human and rat *P2X4* and *P2X7* subunits labeled with GFP as the donor (excitation



at 488 nm, emission at 500–550 nm) or RFP as the acceptor (excitation at 561 nm, emission at 570–650 nm) using a TCS SP5 spectral confocal laser scanning microscope (Leica Microsystems, Wetzlar, Germany) with a 20×0.5 HC PL Fluotar dry objective lens. We placed individual oocytes expressing the indicated constructs in a IBIDI μ -Slide 8-well chamber in oocyte Ringer solution (ORi: 100 mM NaCl, 2.5 mM KCl, 1 mM $MgCl_2$, 1 mM $CaCl_2$, and 5 mM HEPES, pH 7.4) and measured fluorescence signals from the oocyte pole adjacent to the chamber bottom or at the oocyte equator (which had similar FEs; **Figure 2**). Fluorescence signals from donor GFP and acceptor RFP labels were measured before and after acceptor photobleaching at 561 nm using Leica TCS SP5 software or FIJI².

Two-Electrode Voltage Clamp Electrophysiology


We performed the electrophysiological experiments at room temperature ($\sim 22^\circ C$) as previously described (Stolz et al., 2015). We accomplished rapid, reproducible solution exchange by using a small tube-like chamber (0.1 ml) combined with fast superfusion (75 $\mu l/s$). A set of computer-controlled magnetic valves combined with a modified U-tube technique permitted the

bathing solutions to be changed in less than 1 s (Klapperstück et al., 2000). We recorded whole-cell membrane currents via the two-electrode voltage clamp method using 3 M KCl-filled microelectrodes (resistance range 0.8–1.2 M Ω). The currents were recorded and filtered at 100 Hz using an oocyte clamp amplifier (OC-725C; Hamden, CT, United States) and sampled at 85 Hz. We stored and analyzed the data on a personal computer using software written in our department (Superpatch 2000, SP-Analyzer by T. Böhm). Two or three days after cRNA injection, we superfused individual oocytes with ORi solution and impaled the voltage clamp electrodes. To measure currents induced by ATP^{4-} , the agonist of the P2X4 and P2X7 receptors (Klapperstück et al., 2001; Li et al., 2013), we switched the bathing solution to Ca^{2+} - and Mg^{2+} -free ORi (ORi0Ca0Mg: 100 mM NaCl, 2.5 mM KCl, 5 mM HEPES, and 0.1 mM flufenamic acid, pH 7.4) to prevent metal ion complexation of ATP^{4-} . We included flufenamic acid in the ORi0Ca0Mg solution to suppress the large inward conductance that develops in the absence of divalent ions (Kubick et al., 2011). Agonists and antagonists were diluted in the ORi0Ca0Mg solution, as indicated in the figures.

Data Analysis and Presentation

For approximations, statistical analysis, and presentation of the data we used SigmaPlot software (Systat Software).

²<https://fiji.sc>



Statistical data were analyzed using one-way ANOVA. We tested the statistical significance of the differences between means using the Bonferroni multiple comparison *t*-test. The significance of the correlation coefficients was tested using the *t*-test. Statistical significance was set at *p*-value of <0.05.

RESULTS

FRET Demonstrates a Physical and Functional Interaction between P2X4 and P2X7

To investigate whether heteromerization occurs between P2X4 and P2X7 receptor subunits, we used the donor dequenching after acceptor photobleaching FRET quantification technique

(Zheng, 2006; Ma et al., 2014). GFP- or RFP-dependent fluorescence was measured by laser scanning fluorimetry at the oocyte equator or at the oocyte pole in contact with the bottom of the recording chamber before (**Figure 1A**) and after (**Figure 1B**) photobleaching of the RFP-labeled acceptor construct. The FRET efficiency was visualized using the microscope software (**Figure 1C**) following quantitative evaluation (as demonstrated in **Figure 2**). The percentage increase in GFP fluorescence at different bleaching regions was calculated using Equation 1:

$$\text{Donor recovery} = 1 - F_{D,\text{pre}}/F_{D,\text{post}}$$


where $F_{D,\text{pre}}$ and $F_{D,\text{post}}$ are the mean fluorescence signals pre- and post-bleaching, respectively, for the donor GFP at bleached regions. The percentage increase in GFP fluorescence was plotted against the percentage decrease in RFP fluorescence, as calculated using Equation 2:

$$\text{Acceptor bleach} = 1 - F_{A,\text{post}}/F_{A,\text{pre}}$$

where $F_{A,\text{pre}}$ and $F_{A,\text{post}}$ are the mean pre- and post-bleaching fluorescence signals of the acceptor RFP. Extrapolation to 100% acceptor bleaching yielded the FE (Nashmi et al., 2003). FE values measured at the oocyte pole adjacent to the recording chamber were not significantly different from those measured at the oocyte equator (marked “P” and “E”, respectively, in **Figure 2**).

Negative controls had negative FE values (**Figure 2A**) due to the reduction in GFP fluorescence during acceptor photobleaching (**Figure 2B**). A maximal FRET efficiency of 0.148 was measured in oocytes expressing the P2X4-GFP-RFP tandem by extrapolation of the regression line shown in **Figure 2C** to 1.0. A representative example of measurements of a positive control (i.e., oocytes coexpressing P2X4-GFP and P2X4-RFP subunits) is shown in **Figure 2D**.

Mean FRET measurements for different P2X4 and P2X7 constructs labeled with GFP or RFP are depicted in **Figure 3**. As negative controls, we coexpressed RFP-labeled P2X4 or P2X7 constructs with the tetrameric hTRPV2 channel, the pentameric human glycine receptor $\alpha 1$ hGLYRA1, or the pentameric invertebrate glutamate-gated chloride channel GluCl. FRET values for each of these combinations did not significantly differ from -0.019 (determined for the negative control example shown in **Figure 1**). The largest FRET signals were measured for the C-terminal tandemly labeled proteins hP2X4-GFP-RFP and hP2X7-GFP-RFP, and for the P2X4 constructs with single fluorescent labels in the extracellular domain ($^{122}\text{GFP-P2X4} + ^{122}\text{RFP-P2X4}$). Robust FRET signals were also measured after coexpressing the C-terminally labeled positive controls P2X4-GFP and P2X4-RFP. Coexpression of P2X4-GFP with full-length P2X7-RFP did not result in significant FRET signals, but a significant FRET signal was obtained when C-terminally labeled truncated P2X7¹⁻⁴⁰⁸ and P2X4 were coexpressed. These values were similar to the FRET efficiencies measured after coexpression of C-terminally GFP- or RFP-labeled truncated hP2X7¹⁻⁴⁰⁸ with full-length P2X7-RFP or P2X7-GFP subunits, respectively. We consider these combinations as quasi-positive



controls because we previously showed that the truncated hP2X7 can co-assemble (i.e., physically interact) and function together with full-length hP2X7 receptor subunits (Becker et al., 2008). Much larger FRET signals were obtained for coexpressed P2X4 constructs with GFP or RFP located within the extracellular domain. Similarly, relatively higher FRET values were measured for P2X7 subunits with the GFP label located in the extracellular domain when coexpressed with P2X4 subunits with an extracellularly located RFP label. These results clearly indicate a close physical interaction between P2X4 and P2X7 subunits.

Next, we tested whether the significant FE values between GFP- and RFP-labeled subunits were due to non-specific FRET, i.e., interaction of homotrimeric P2X4 and P2X7 receptors. In this case, the FE should increase with higher levels of protein expression. However, the FE did not correlate with the strength of the fluorescence signal (Supplementary Figure 1).


Fluorophore-labeled P2X constructs formed functional ion channels (shown in Figure 4). Although the current amplitudes varied considerably depending on the presence

and location of the fluorescent label (Figures 4A,B), the characteristics of P2X4-dependent (inactivating) and P2X7-dependent (slowly increasing) currents were retained (Figures 4A,C).

The Physical P2X4/P2X7 Interaction Is Not Associated with a Novel Functional Phenotype

Kinetics of Coexpressed hP2X4 and hP2X7 Receptor Subunits

We first tested whether coexpression changes the kinetics of hP2X4- and hP2X7-dependence channel currents. We therefore compared the mean ATP-induced currents in oocytes expressing hP2X4 and/or hP2X7 (Figure 5A). hP2X4-dependent currents displayed the typical inactivating behavior, leading to a peak current at about 1 s after ATP application. In contrast, currents in hP2X7-expressing oocytes showed the typical slowly activating non-saturating behavior during the 12 s of ATP application (Klapperstück et al., 2001; Stolz et al., 2015). In hP2X4/hP2X7-coexpressing oocytes, a peak ATP-induced



current was barely detectable, and the slope of the slowly activating current was reduced compared with hP2X7-dependent currents. In **Figure 5B**, the current measured in hP2X4 and hP2X7 coexpressing oocytes is compared with the sum of the currents measured in oocytes expressing each protein alone. The current amplitudes were not significantly different throughout the entire time course of ATP application and withdrawal. The simplest explanation for this observation is that hP2X4 and hP2X7 do not functionally interact in oocytes, and that the measured ATP-dependent current is simply the sum of the separate hP2X4- and hP2X7-dependent components.


ATP Dependence of Coexpressed hP2X4 and hP2X7 Receptor Subunits

We next investigated the ATP concentration dependency of the current in oocytes coexpressing hP2X4 and hP2X7 subunits (**Figure 6A**). As P2X4-dependent currents show long-lasting desensitization following ATP application, we normalized all maximal current amplitudes to the maximal current amplitude measured during a foregoing application of 0.1 mM ATP. The concentration–response curve for oocytes coexpressing hP2X4 and hP2X7 was located between the curves for those expressing hP2X4 or hP2X7 alone, indicating that hP2X4 is dominant at low ATP concentrations and hP2X7 is dominant at high ATP concentrations. At low ATP concentrations, the relative currents measured in oocytes coexpressing hP2X4 and hP2X7 were smaller than those in oocytes expressing hP2X4 only.

This results from normalization to the current amplitudes evoked by 0.1 mM ATP. This ATP concentration evokes both hP2X4- and hP2X7-dependent currents, leading to a smaller relative current at ATP concentrations of 1–10 μ M, although these are predominantly mediated by hP2X4. Similarly, at high ATP concentrations, the relative currents measured in hP2X4/hP2X7-coexpressing oocytes were smaller than those measured in oocytes expressing hP2X7 only. This also results from normalization to the first application of 0.1 mM ATP, where the hP2X4 component contributes. The hP2X4 component largely undergoes desensitization at the second ATP application, as shown in **Figures 6B–D**, where the mean currents measured in hP2X4/hP2X7-coexpressing oocytes at different ATP concentrations are displayed. At high ATP concentrations (**Figure 6B**), a slowly activating current, driven by the dominant hP2X7 component, was measured. In contrast, at very low ATP concentrations (**Figure 6D**), the inactivating current became apparent. At the intermediate ATP concentration of 1 μ M (**Figure 6C**), hP2X4- and hP2X7-dependent currents were almost completely balanced, leading to almost constant current amplitudes over the 2–12 s time course of the ATP application.

Effect of P2X4 Modulators on Coexpressed hP2X4 and hP2X7 Receptor Subunits

We next investigated the pharmacologic phenotype of coexpressed hP2X4 and hP2X7 using subunit-specific



activators and inhibitors. First, we investigated the effects of ivermectin, which potentiates P2X4-dependent ATP-induced ion currents (Priel and Silberberg, 2004). As shown in **Figure 7**, coapplication of ivermectin and ATP increased hP2X4-dependent currents (**Figure 7A**) but not hP2X7-dependent currents (**Figure 7B**). Currents in hP2X4/hP2X7-coexpressing oocytes were also stimulated by ivermectin (**Figure 7C**). However, the increased current amplitude was not significantly different from the sum of hP2X4- and hP2X7-dependent currents, as measured in oocytes expressing each P2X subtype.

Next, we measured the effect of adding PSB-15417, a P2X4 receptor-selective inhibitor. The addition of 10 μ M PSB-15417 completely blocked hP2X4-mediated currents (**Figure 8**, column 1 vs. column 2), whereas hP2X7-dependent currents were reduced by only 18% (**Figure 8**, column 3 vs. column 4). To calculate the extent of PSB-15417 inhibition of hP2X4/hP2X7-coexpressed subunits, we assumed that in oocytes coexpressing hP2X4 and hP2X7 (**Figure 8**, column 5) 32% of the ATP-induced current resulted from P2X4 and 68% from P2X7,


based on the amplitudes measured in oocytes expressing hP2X4 (**Figure 8**, column 1) or hP2X7 (**Figure 8**, column 3) alone and the fact that hP2X7-dependent currents do not undergo desensitization (**Figure 5**). By assuming that PSB-15417 has the same effect on hP2X4- and hP2X7-mediated currents in hP2X4/hP2X7-coexpressing oocytes as in oocytes expressing hP2X4 or hP2X7 alone (i.e., reduction by 100 or 18%, respectively), a theoretical value for the current remaining after applying PSB-15417 to hP2X4/hP2X7-coexpressing oocytes was calculated (**Figure 8**, column 7). This value was not significantly different from the measured value (**Figure 8**, column 6).

Effect of P2X7 Agonist and Antagonists on Coexpressed hP2X4 and hP2X7 Subunits

Oocytes expressing hP2X4, hP2X7, and hP2X4/hP2X7 were treated with the P2X7 agonist BzATP (**Figure 9**). As we expected from previous reports (von Kügelgen, 2008), 0.1 mM BzATP was less effective against hP2X4 compared with 0.1 mM ATP (**Figure 9A**). However, it was much more effective against hP2X7 than against hP2X4 (**Figure 9B**). The amplitude of the BzATP-stimulated current in hP2X4/hP2X7-coexpressing oocytes (**Figure 9C**) was equal to the sum of the current amplitudes measured in oocytes expressing either hP2X4 or hP2X7 alone (**Figure 9D**).

Next, we tested the effects of three different P2X7 antagonists/blockers on the currents in hP2X4/hP2X7-coexpressing oocytes. P2X7-dependent ion currents (North, 2002; Seyffert et al., 2004; Li et al., 2013) and Ca^{2+} signals (Pippel et al., 2015) are blocked by Mg^{2+} ions. Consistent with these findings, we found that Mg^{2+} coapplication reduces ATP-induced currents in hP2X7-expressing oocytes (**Figure 10B**) but not in those expressing hP2X4 (**Figure 10A**). The inhibitory effect of Mg^{2+} on hP2X4/hP2X7-coexpressing oocytes (**Figure 10C**) was equal to the sum of the separate effects of Mg^{2+} on hP2X4 and on hP2X7 (**Figure 10D**). The P2X7 antagonist oxidized ATP (oATP) (North, 2002; von Kügelgen, 2008) had qualitatively similar effects (**Figure 11**).

We investigated the effects of the P2X7-specific blocker A438079 (Nelson et al., 2006) using a protocol similar to the one used for PSB-15417 (**Figure 12**). As before, we normalized the amplitudes of the ATP-induced currents to those measured during a previous application of 0.1 mM ATP. Owing to hP2X4 desensitization, the amplitude of the second ATP-induced current was reduced by 70% on average (**Figure 12**, column 1 vs. column 2). Application of A438079 did not change this desensitization rate (**Figure 12**, column 3 vs. column 4), indicating a lack of effect on hP2X4. In contrast, P2X7-dependent currents did not display desensitization (**Figure 12**, column 5 vs. column 6). Considering 70% desensitization of hP2X4, the percentage of functional P2X4 in oocytes coexpressing P2X4 and P2X7 was calculated to be 20% (**Figure 12**, column 9 vs. column 10). By taking this into account, as well as the mean blocking effect of A438079 of 81% (**Figure 12**, column 7 vs.



column 8), we calculated the ATP-induced current amplitude in hP2X4/hP2X7-coexpressing oocytes that was not blocked by A438079 (**Figure 12**, column 13). The calculated value for the amplitude was not significantly different from the measured value (**Figure 12**, column 12).



DISCUSSION


FRET as a Tool to Investigate Physical Interaction of P2X4 and P2X7 Receptor Subunits

Our FRET measurements indicate a close association between P2X4 and P2X7 receptor subunits. Furthermore, FRET values were similar to those of positive controls (coexpressed homomeric GFP- and RFP-labeled P2X4 or P2X7 constructs) when the fluorophore was incorporated within the extracellular loop. Similar FE values were obtained for homomers and heteromers, indicating an abundance of P2X4/P2X7 heteromers. We were unable to study several P2X4 and P2X7 constructs in which the label was incorporated within the extracellular domain because of their weak expression. For extracellularly labeled constructs with reasonable expression levels, FEs were much larger compared with the FEs of C-terminally fluorescence-labeled constructs. The differences in FRET efficiency are consistent with a model in which the fluorophore moiety has approximately the same relative distance from the (outer)

membrane surface in both ectodomain-labeled P2X4 and P2X7 proteins. In C-terminally labeled constructs, the location of the fluorophore moiety relative to the (inner) membrane surface is strongly influenced by the length of the C-terminal tail, which is much shorter in the hP2X4 subunit (29 residues) than in the hP2X7 subunit (\sim 300 residues; see Supplementary Figures 2–27). Therefore, FE was very low or absent when C-terminally fluorescence-labeled P2X4 and P2X7 constructs were coexpressed. In contrast, coexpression of C-terminally labeled P2X4 and truncated P2X7^{1–408} resulted in significant FE values. This indicates that the C-terminus is located far from the “trunk” of the P2X7 subunit (residues 1–408). Importantly, all of the sequence elements responsible for P2X subunit assembly are located within the ectodomain; therefore, C-terminal truncation does not affect trimerization (Duckwitz et al., 2006). We also previously reported that truncated hP2X7^{1–408} subunits can assemble into functional trimers (Becker et al., 2008).

These findings contradict a previous FRET study of cyan fluorescent protein (CFP)- and yellow fluorescent protein (YFP)-labeled P2X proteins expressed in human embryonic kidney cells, which reported a larger FE for homomeric P2X7 than for homomeric P2X4 (Young et al., 2008). The authors concluded that longer rather than shorter P2X C-termini are more likely to interact. In another study using the same expression system, the P2X4/P2X7 interaction was investigated by measuring sensitized emissions of the acceptor YFP by Spectra-FRET (Perez-Flores et al., 2015). The authors reported that a significant FE for coexpressed P2X4/P2X7 was only obtained after activating the





P2X7 receptor with BzATP or high ATP concentrations. No measurable FE was obtained for truncated P2X7^{1–418} constructs. The reason for the discrepancies between these results and ours is unclear, but might be caused by differences in the choice of the expression system and the P2X constructs.

It is possible that P2X4 and P2X7 subunits interact not only as heteromers but also as homomers. Indications of close contact of P2X4 and P2X7 homomers have been reported (Boumechache et al., 2009; Weinhold et al., 2010). In contrast, atomic force microscopy measurements only rarely found dimers of distinct homotrimeric P2X4 and P2X7 receptors (Antonio et al., 2011). Although we cannot completely rule out the possibility of self-association for homotrimeric P2X4 and P2X7 receptors, in our FRET experiments, we consider it unlikely for the following reason. The probability of non-specific FRET signals is enhanced with increasing levels of subunit expression and diminished at low expression levels. However, we did not observe such a correlation (Supplementary Figure 1). It was calculated that non-specific bystander effects occur at a fluorescence molecule density of ≥ 2000 molecules/ μm^2 (Clayton and Chattopadhyay, 2014). Given a surface area A of *Xenopus*

oocytes of about $2 \times 10^7 \mu\text{m}^2$ (Lin-Moshier and Marchant, 2013), a single channel current amplitude i at -40 mV of ~ 0.4 pA, an open probability P_o (1 mM ATP) of about 0.2 (Riedel et al., 2007), and a maximal P2X7-mediated whole-cell current I of 2000 nA (Figure 4), the molecule density $D = I/(iP_oA) = 1.25$ molecules/ μm^2 for fluorescence-labeled P2X7 receptors, or 3.75 P2X7 subunits/ μm^2 , far higher than the critical expression density for bystander FRET. Furthermore, the lack of FRET signals for our negative controls argue against non-specific FRET. The same line of argument holds against a possible non-specific interaction between GFP- and RFP-labeled constructs.

Do Coexpressed P2X4 and P2X7 Receptor Subunits Have a Distinct Electrophysiological Phenotype?

Our evidence for a physical interaction between P2X4 and P2X7 subunits within heteromers led us to investigate the functional consequences of this interaction by measuring hP2X4- and hP2X7-dependent ion currents in *Xenopus* oocytes. For this, we studied the current time course, the ATP concentration dependency of current amplitudes, and the effect of P2X4- or P2X7-specific drugs in P2X4/P2X7-coexpressing oocytes. For each parameter, the result could be explained by an additive effect of the individual hP2X4 and hP2X7 current components. Likewise, the simplest explanation for the time course of ATP-activated currents in hP2X4/hP2X7-coexpressing oocytes is that only homomeric hP2X4 and hP2X7 receptors are formed, with independent functions. Furthermore, the simplest explanation for the ATP concentration-dependence of currents in oocytes coexpressing hP2X4 and hP2X7 is that at low ATP concentrations ($< 10 \mu\text{M}$) only hP2X4 receptors (with high ATP sensitivity) are activated, whereas at higher ATP concentrations additional hP2X7 receptor channels (with low ATP sensitivity) are opened. This explanation does not require the formation of P2X4/P2X7 heteromers with a distinct ATP concentration dependency. Similarly, the effects of P2X4- or P2X7-specific pharmacological agents in oocytes coexpressing hP2X4 and hP2X7 can be explained by their actions on homomers of the targeted subtype only.

The lack of a functional interaction is consistent with the functionally independent P2X4 and P2X7 phenotypes reported in rat cortical microglia (Visentin et al., 1999). In contrast, functional P2X4/P2X7 interactions have been reported in airway ciliated cells (Ma et al., 2006), macrophages (Babelova et al., 2009; Kawano et al., 2012a,b), dendritic cells (Sakaki et al., 2013), and gingival epithelial cells (Hung et al., 2013).

In the present study, it is difficult to reconcile evidence for a physical interaction in the form of heteromers, as demonstrated by the FRET measurements, with the lack of a new functional phenotype, as indicated by the electrophysiological recordings. A possible explanation is that heteromers exist, but the phenotype is either P2X4-like or P2X7-like. This might depend on the presence of a single P2X4 or P2X7 subunit driving the dominant phenotype or on which subunit is incorporated twice into the

trimer. Further study into the molecular mechanism of P2X receptor function is therefore necessary.

AUTHOR CONTRIBUTIONS

MS, KP, and AP performed experiments and evaluated data. MK designed study, performed experiments, evaluated data and critically read the manuscript. CM provided drugs and critically read the manuscript. UB made the P2X constructs. GS designed the study, evaluated data and wrote the manuscript. FM designed the study, performed experiments, evaluated data and wrote the manuscript.

FUNDING

We thank the Deutsche Forschungsgemeinschaft (Ma1581/15–3; Schm536/9–3) for financial support. Open access publishing

REFERENCES

- Antonio, L. S., Stewart, A. P., Xu, X. J., Varanda, W. A., Murrell-Lagnado, R. D., and Edwardson, J. M. (2011). P2X4 receptors interact with both P2X2 and P2X7 receptors in the form of homotrimers. *Br. J. Pharmacol.* 163, 1069–1077. doi: 10.1111/j.1476-5381.2011.01303.x
- Aschrafi, A., Sadtler, S., Niculescu, C., Rettinger, J., and Schmalzing, G. (2004). Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes. *J. Mol. Biol.* 342, 333–343. doi: 10.1016/j.jmb.2004.06.092
- Babelova, A., Moreth, K., Tsalastra-Greul, W., Zeng-Brouwers, J., Eickelberg, O., Young, M. F., et al. (2009). Biglycan: a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. *J. Biol. Chem.* 284, 24035–24048. doi: 10.1074/jbc.M109.014266
- Baconguis, I., Hattori, M., and Gouaux, E. (2013). Unanticipated parallels in architecture and mechanism between ATP-gated P2X receptors and acid sensing ion channels. *Curr. Opin. Struct. Biol.* 23, 277–284. doi: 10.1016/j.sbi.2013.04.005
- Becker, D., Woltersdorf, R., Boldt, W., Schmitz, S., Braam, U., Schmalzing, G., et al. (2008). The P2X7 carboxyl tail is a regulatory module of P2X7 receptor channel activity. *J. Biol. Chem.* 283, 25725–25734. doi: 10.1074/jbc.M803855200
- Boumechache, M., Masin, M., Edwardson, J. M., Gorecki, D. C., and Murrell-Lagnado, R. (2009). Analysis of assembly and trafficking of native P2X4 and P2X7 receptor complexes in rodent immune cells. *J. Biol. Chem.* 284, 13446–13454. doi: 10.1074/jbc.M901255200
- Braman, J., Papworth, C., and Greener, A. (1996). Site-directed mutagenesis using double-stranded plasmid DNA templates. *Methods Mol. Biol.* 57, 31–44. doi: 10.1385/0-89603-332-5:31
- Burnstock, G., and Knight, G. E. (2004). Cellular distribution and functions of P2 receptor subtypes in different systems. *Int. Rev. Cytol.* 240, 31–304. doi: 10.1016/S0074-7696(04)40002-3
- Büttner, C., Sadtler, S., Leyendecker, A., Laube, B., Griffon, N., Betz, H., et al. (2001). Ubiquitination precedes internalization and proteolytic cleavage of plasma membrane-bound glycine receptors. *J. Biol. Chem.* 276, 42978–42985. doi: 10.1074/jbc.M102121200
- Clayton, A. H., and Chattopadhyay, A. (2014). Taking care of bystander FRET in a crowded cell membrane environment. *Biophys. J.* 106, 1227–1228. doi: 10.1016/j.bpj.2014.02.004
- Craigie, E., Birch, R. E., Unwin, R. J., and Wildman, S. S. (2013). The relationship between P2X4 and P2X7: a physiologically important interaction? *Front. Physiol.* 4:216. doi: 10.3389/fphys.2013.00216
- Di Virgilio, F. (2007). Liaisons dangereuses: P2X7 and the inflammasome. *Trends Pharmacol. Sci.* 28, 465–472. doi: 10.1016/j.tips.2007.07.002

was supported by the Publikationsfonds of the Martin-Luther University Halle.

ACKNOWLEDGMENTS

We thank Dr. Cora Büttner for cloning the P2X7 receptor subunit from rat brain RNA during her Ph.D. studies (1997–2001) at the Department of Pharmacology, Biocenter, Johann Wolfgang Goethe–University of Frankfurt.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2017.00860/full#supplementary-material>

- Dopychai, A., Pokam, C. F., and Schmalzing, G. (2015). Aromatic residues in the transmembrane helices play an essential role in the homopentameric assembly of the GluCl α . *Biophys. J.* 108:431a. doi: 10.1016/j.bpj.2014.11.2356
- Duckwitz, W., Hausmann, R., Aschrafi, A., and Schmalzing, G. (2006). P2X5 subunit assembly requires scaffolding by the second transmembrane domain and a conserved aspartate. *J. Biol. Chem.* 281, 39561–39572. doi: 10.1074/jbc.M606113200
- Flittiger, B., Klapperstück, M., Schmalzing, G., and Markwardt, F. (2010). Effects of protons on macroscopic and single-channel currents mediated by the human P2X7 receptor. *Biochim. Biophys. Acta Biomembr.* 1798, 947–957. doi: 10.1016/j.bbmem.2010.01.023
- Gloor, S., Pongs, O., and Schmalzing, G. (1995). A vector for the synthesis of cRNAs encoding Myc epitope-tagged proteins in *Xenopus laevis* oocytes. *Gene* 160, 213–217. doi: 10.1016/0378-1119(95)00226-V
- Grudzien-Nogalska, E., Stepinski, J., Jemielity, J., Zuberek, J., Stolarski, R., Rhoads, R. E., et al. (2007). Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability. *Methods Enzymol.* 431, 203–227. doi: 10.1016/S0076-6879(07)31011-2
- Guo, C., Masin, M., Qureshi, O. S., and Murrell-Lagnado, R. D. (2007). Evidence for functional P2X4/P2X7 heteromeric receptors. *Mol. Pharmacol.* 72, 1447–1456. doi: 10.1124/mol.107.035980
- Habermacher, C., Dunning, K., Chataigneau, T., and Grutter, T. (2015). Molecular structure and function of P2X receptors. *Neuropharmacology* 104, 18–30. doi: 10.1016/j.neuropharm.2015.07.032
- Hausmann, R., Rettinger, J., Gerevich, Z., Meis, S., Kassack, M. U., Illes, P., et al. (2006). The suramin analog 4,4',4''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. *Mol. Pharmacol.* 69, 2058–2067. doi: 10.1124/mol.106.022665
- Hibbs, R. E., and Gouaux, E. (2011). Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* 474, 54–60. doi: 10.1038/nature10139
- Hung, S. C., Choi, C. H., Said-Sadier, N., Johnson, L., Atanasova, K. R., Sellami, H., et al. (2013). P2X4 assembles with P2X7 and pannexin-1 in gingival epithelial cells and modulates ATP-induced reactive oxygen species production and inflammasome activation. *PLOS ONE* 8:e70210. doi: 10.1371/journal.pone.0070210
- Kawano, A., Tsukimoto, M., Mori, D., Noguchi, T., Harada, H., Takenouchi, T., et al. (2012a). Regulation of P2X7-dependent inflammatory functions by P2X4 receptor in mouse macrophages. *Biochem. Biophys. Res. Commun.* 420, 102–107. doi: 10.1016/j.bbrc.2012.02.122
- Kawano, A., Tsukimoto, M., Noguchi, T., Hotta, N., Harada, H., Takenouchi, T., et al. (2012b). Involvement of P2X4 receptor in P2X7 receptor-dependent cell

- death of mouse macrophages. *Biochem. Biophys. Res. Commun.* 419, 374–380. doi: 10.1016/j.bbrc.2012.01.156
- Kawate, T., Michel, J. C., Birdsong, W. T., and Gouaux, E. (2009). Crystal structure of the ATP-gated P2X4 ion channel in the closed state. *Nature* 460, 592–598. doi: 10.1038/nature08198
- Klapperstück, M., Büttner, C., Böhm, T., Schmalzing, G., and Markwardt, F. (2000). Characteristics of P2X7 receptors from human B lymphocytes expressed in *Xenopus oocytes*. *Biochim. Biophys. Acta* 1467, 444–456. doi: 10.1016/S0005-2736(00)00245-5
- Klapperstück, M., Büttner, C., Schmalzing, G., and Markwardt, F. (2001). Functional evidence of distinct ATP activation sites at the human P2X7 receptor. *J. Physiol. (Lond.)* 534, 25–35. doi: 10.1111/j.1469-7793.2001.00025.x
- Kovalic, D., Kwak, J. H., and Weisblum, B. (1991). General method for direct cloning of DNA fragments generated by the polymerase chain reaction. *Nucleic Acids Res.* 19:4560. doi: 10.1093/nar/19.16.4560
- Kubick, C., Schmalzing, G., and Markwardt, F. (2011). The effect of anions on the human P2X7 receptor. *Biochim. Biophys. Acta Biomembr.* 1808, 2913–2922. doi: 10.1016/j.bbame.2011.08.017
- Lewis, C., Neidhart, S., Holy, C., North, R. A., Buell, G., and Surprenant, A. (1995). Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. *Nature* 377, 432–435. doi: 10.1038/377432a0
- Li, M., Silberberg, S. D., and Swartz, K. J. (2013). Subtype-specific control of P2X receptor channel signaling by ATP and Mg²⁺. *Proc. Natl. Acad. Sci. U.S.A.* 110, E3455–E3463. doi: 10.1073/pnas.1308088110
- Lin-Moshier, Y., and Marchant, J. S. (2013). The *Xenopus oocyte*: a single-cell model for studying Ca²⁺ signaling. *Cold Spring Harb. Protoc.* 2013.pdb.top066308. doi: 10.1101/pdb.top066308
- Ma, L., Yang, F., and Zheng, J. (2014). Application of fluorescence resonance energy transfer in protein studies. *J. Mol. Struct.* 1077, 87–100. doi: 10.1016/j.molstruc.2013.12.071
- Ma, W. Y., Korngreen, A., Weil, S., Cohen, E. B. T., Priel, A., Kuzin, L., et al. (2006). Pore properties and pharmacological features of the P2X receptor channel in airway ciliated cells. *J. Physiol.* 571, 503–517. doi: 10.1113/jphysiol.2005.103408
- Nashmi, R., Dickinson, M. E., McKinney, S., Jareb, M., Labarca, C., Fraser, S. E., et al. (2003). Assembly of $\alpha 4\beta 2$ nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons. *J. Neurosci.* 23, 11554–11567.
- Nelson, D. W., Gregg, R. J., Kort, M. E., Perez-Medrano, A., Voight, E. A., Wang, Y., et al. (2006). Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. *J. Med. Chem.* 49, 3659–3666. doi: 10.1021/jm051202e
- Nicke, A. (2008). Homotrimeric complexes are the dominant assembly state of native P2X7 subunits. *Biochem. Biophys. Res. Commun.* 377, 803–808. doi: 10.1016/j.bbrc.2008.10.042
- Nicke, A., Bäumert, H. G., Rettinger, J., Eichele, A., Lambrecht, G., Mutschler, E., et al. (1998). P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. *EMBO J.* 17, 3016–3028. doi: 10.1093/emboj/17.11.3016
- North, R. A. (2002). Molecular physiology of P2X receptors. *Physiol. Rev.* 82, 1013–1067. doi: 10.1152/physrev.00015.2002
- Perez, K., Yeam, I., Jahn, M. M., and Kang, B. C. (2006). Megaprimer-mediated domain swapping for construction of chimeric viruses. *J. Virol. Methods* 135, 254–262. doi: 10.1016/j.jviromet.2006.03.020
- Perez-Flores, G., Levesque, S. A., Pacheco, J., Vaca, L., Lacroix, S., Perez-Cornejo, P., et al. (2015). The P2X7/P2X4 interaction shapes the purinergic response in murine macrophages. *Biochem. Biophys. Res. Commun.* 467, 484–490. doi: 10.1016/j.bbrc.2015.10.025
- Petersen, T. N., Brunak, S., von, H. G., and Nielsen, H. (2011). SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat. Methods* 8, 785–786. doi: 10.1038/nmeth.1701
- Pippel, A., Befler, B., Klapperstück, M., and Markwardt, F. (2015). Inhibition of antigen receptor-dependent Ca²⁺ signals and NF-AT activation by P2X7 receptors in human B lymphocytes. *Cell Calcium* 57, 275–289. doi: 10.1016/j.ceca.2015.01.010
- Pippel, A., Stolz, M., Woltersdorf, R., Kless, A., Schmalzing, G., and Markwardt, F. (2017). Localization of the gate and selectivity filter of the full-length P2X7 receptor. *Proc. Natl. Acad. Sci. U.S.A.* 114, E2156–E2165. doi: 10.1073/pnas.1610414114
- Praetorius, H. A., and Leipziger, J. (2009). ATP release from non-excitable cells. *Purinergic Signal.* 5, 433–446. doi: 10.1007/s11302-009-9146-2
- Priel, A., and Silberberg, S. D. (2004). Mechanism of ivermectin facilitation of human P2X4 receptor channels. *J. Gen. Physiol.* 123, 281–293. doi: 10.1085/jgp.200308986
- Rettinger, J., Schmalzing, G., Damer, S., Müller, G., Nickel, P., and Lambrecht, G. (2000). The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor. *Neuropharmacology* 39, 2044–2053. doi: 10.1016/S0028-3908(00)00022-8
- Riedel, T., Lozinsky, I., Schmalzing, G., and Markwardt, F. (2007). Kinetics of P2X7 receptor-operated single channels currents. *Biophys. J.* 92, 2377–2391. doi: 10.1529/biophysj.106.091413
- Sakaki, H., Fujiwaki, T., Tsukimoto, M., Kawano, A., Harada, H., and Kojima, S. (2013). P2X4 receptor regulates P2X7 receptor-dependent IL-1 β and IL-18 release in mouse bone marrow-derived dendritic cells. *Biochem. Biophys. Res. Commun.* 432, 406–411. doi: 10.1016/j.bbrc.2013.01.135
- Saul, A., Hausmann, R., Kless, A., and Nicke, A. (2013). Heteromeric assembly of P2X subunits. *Front. Cell Neurosci.* 7:250. doi: 10.3389/fncel.2013.00250
- Seyffert, C., Schmalzing, G., and Markwardt, F. (2004). Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors. *Curr. Top. Med. Chem.* 4, 1719–1730. doi: 10.2174/1568026043387160
- Stolz, M., Klapperstück, M., Kendzierski, T., Detro-Dassen, S., Panning, A., Schmalzing, G., et al. (2015). Homodimeric anoctamin-1, but not homodimeric anoctamin-6, is activated by calcium increases mediated by the P2Y1 and P2X7 receptors. *Pflügers Arch.* 467, 2121–2140. doi: 10.1007/s00424-015-1687-3
- Surprenant, A., and North, R. A. (2008). Signaling at purinergic P2X receptors. *Annu. Rev. Physiol.* 71, 333–359. doi: 10.1146/annurev.physiol.70.113006.100630
- Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., and Buell, G. (1996). The cytolitic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). *Science* 272, 735–738. doi: 10.1126/science.272.5262.735
- Torres, G. E., Egan, T. M., and Voigt, M. M. (1999). Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. *J. Biol. Chem.* 274, 6653–6659. doi: 10.1074/jbc.274.10.6653
- Visentini, S., Renzi, M., Frank, C., Greco, A., and Levi, G. (1999). Two different ionotropic receptors are activated by ATP in rat microglia. *J. Physiol.* 519, 723–736. doi: 10.1111/j.1469-7793.1999.0723n.x
- von Kügelgen, I. (2008). Pharmacology of mammalian P2X and P2Y receptors. *Biotrend Rev.* 3, 1–10.
- Weinhold, K., Krause-Buchholz, U., Rodel, G., Kasper, M., and Barth, K. (2010). Interaction and interrelation of P2X7 and P2X4 receptor complexes in mouse lung epithelial cells. *Cell. Mol. Life Sci.* 67, 2631–2642. doi: 10.1007/s00018-010-0355-1
- Xu, J., Chai, H., Ehinger, K., Egan, T. M., Srinivasan, R., Frick, M., et al. (2014). Imaging P2X4 receptor subcellular distribution, trafficking, and regulation using P2X4-pHluorin. *J. Gen. Physiol.* 144, 81–104. doi: 10.1085/jgp.2014.11169
- Young, M. T., Fisher, J. A., Fountain, S. J., Ford, R. C., North, R. A., and Khakh, B. S. (2008). Molecular shape, architecture and size of P2X4 receptors determined using fluorescence resonance energy transfer and electron microscopy. *J. Biol. Chem.* 283, 26241–26251. doi: 10.1074/jbc.M804458200
- Zheng, J. (2006). Spectroscopy-based quantitative fluorescence resonance energy transfer analysis. *Methods Mol. Biol.* 337, 65–77. doi: 10.1385/1-59745-095-2:65

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Schneider, Prudic, Pippel, Klapperstück, Braam, Müller, Schmalzing and Markwardt. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.